OncoCyte Corp Total Liabilities
OncoCyte Corp total liabilities. Based on the latest financial reports, OncoCyte Corp (OCX) has total liabilities worth $50.14 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OCX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of OncoCyte Corp (2013–2024)
Total liabilities of OncoCyte Corp from 2013 to 2024. This chart illustrates how OncoCyte Corp's total liabilities have evolved over time, based on quarterly financial data. Explore OncoCyte Corp long-term investment intensity to see how much of total assets are deployed in long-term investments.
OncoCyte Corp Competitors by Total Liabilities
The table below lists competitors of OncoCyte Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hongli Group Inc. Ordinary Shares
NASDAQ:HLP
|
USA | $14.36 Million |
|
Tae Kyung Ind
KO:015890
|
Korea | ₩389.24 Billion |
|
Likhitha Infrastructure Limited
NSE:LIKHITHA
|
India | Rs512.61 Million |
|
Apex Biotechnology Corp
TW:1733
|
Taiwan | NT$494.69 Million |
|
Micropolis Holding Company
NYSE MKT:MCRP
|
USA | $40.58 Million |
|
Kumho Petro Chemical Co Ltd
KO:011785
|
Korea | ₩2.32 Trillion |
|
Barington/Hilco Acquisition
NASDAQ:BHAC
|
USA | $9.74 Million |
|
Cameo Communications Inc
TW:6142
|
Taiwan | NT$1.20 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down OncoCyte Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is OncoCyte Corp's balance sheet.
Liquidity & Leverage Metrics
OncoCyte Corp Total Liabilities Ratios Explained
OncoCyte Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OncoCyte Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OncoCyte Corp (2013–2024)
The table below shows the annual total liabilities of OncoCyte Corp from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $47.35 Million | -3.94% |
| 2023-12-31 | $49.30 Million | -25.08% |
| 2022-12-31 | $65.80 Million | -30.26% |
| 2021-12-31 | $94.35 Million | +330.10% |
| 2020-12-31 | $21.94 Million | +143.17% |
| 2019-12-31 | $9.02 Million | +48.01% |
| 2018-12-31 | $6.09 Million | +4.85% |
| 2017-12-31 | $5.81 Million | +26.78% |
| 2016-12-31 | $4.58 Million | +98.14% |
| 2015-12-31 | $2.31 Million | -68.86% |
| 2014-12-31 | $7.43 Million | +59.03% |
| 2013-12-31 | $4.67 Million | -- |
About OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test tha… Read more